Ring-opened aminothienopyridazines as novel tau aggregation inhibitors

M. Moir, S. W. Chua, T. Reekie, A. D. Martin, A. Ittner, L. M. Ittner, M. Kassiou

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Aminothienopyridazines (ATPZs) have demonstrated efficacy, in vitro, as tau protein aggregation inhibitors. Modifications were made to the ATPZ scaffold to determine the importance of certain structural features for activity. More specifically, ring-opened analogues detached at the nitrogen-nitrogen bond of the pyridazine, were synthesized and their inhibitory activity evaluated. Preliminary data suggests that the ring-opened structures retain inhibitory activity, independent of tau oxidation. The structures detailed represent the beginnings of a deconstruction-reconstruction-elaboration study, with the aim of identifying simpler scaffolds, which retain activity and can be optimized in terms of physiochemical properties.

Original languageEnglish
Pages (from-to)1275-1282
Number of pages8
Issue number6
Publication statusPublished - Jun 2017
Externally publishedYes


  • Aminothienopyridazines (ATPZs
  • Alzheimer's disease
  • tau protein aggregation inhibitors


Dive into the research topics of 'Ring-opened aminothienopyridazines as novel tau aggregation inhibitors'. Together they form a unique fingerprint.

Cite this